PL2295049T3 - Leczenie chorób autoimmunologicznych - Google Patents

Leczenie chorób autoimmunologicznych

Info

Publication number: PL2295049T3
Authority: PL; Poland
Prior art keywords: autoimmune diseases; treatment; neuritis; uveitis; invention describes
Prior art date: 2005-09-09

Application number

PL10174280T

Other languages

English (en)

Inventor

Rainer Albert

Nigel Graham Cooke

Barbara Nuesslein-Hildesheim

Sven Weiler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-09

Filing date

2006-09-07

Publication date

2015-04-30

2006-09-07 Application filed by Novartis Ag filed Critical Novartis Ag

2015-04-30 Publication of PL2295049T3 publication Critical patent/PL2295049T3/pl

Links

208000023275 Autoimmune disease Diseases 0.000 title abstract 2
206010029240 Neuritis Diseases 0.000 abstract 2
206010046851 Uveitis Diseases 0.000 abstract 1
150000001414 amino alcohols Chemical class 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL10174280T 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych PL2295049T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US71599005P	2005-09-09	2005-09-09
EP10174280.7A EP2295049B1 (en)	2005-09-09	2006-09-07	Treatment of autoimmune diseases
EP06793341A EP1926483B1 (en)	2005-09-09	2006-09-07	Treatment of autoimmune diseases

Publications (1)

Publication Number	Publication Date
PL2295049T3 true PL2295049T3 (pl)	2015-04-30

Family

ID=37056992

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL06793341T PL1926483T3 (pl)	2005-09-09	2006-09-07	Leczenie chorób autoimmunologicznych
PL10174280T PL2295049T3 (pl)	2005-09-09	2006-09-07	Leczenie chorób autoimmunologicznych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL06793341T PL1926483T3 (pl)	2005-09-09	2006-09-07	Leczenie chorób autoimmunologicznych

Country Status (28)

Country	Link
US (1)	US20080200438A1 (pl)
EP (2)	EP1926483B1 (pl)
JP (4)	JP5244598B2 (pl)
KR (3)	KR101476451B1 (pl)
CN (1)	CN101257899B (pl)
AT (1)	ATE489948T1 (pl)
AU (2)	AU2006289100B2 (pl)
BR (1)	BRPI0615906A2 (pl)
CA (2)	CA2620554C (pl)
CY (1)	CY1111285T1 (pl)
DE (1)	DE602006018629D1 (pl)
DK (2)	DK1926483T3 (pl)
ES (2)	ES2529724T3 (pl)
IL (2)	IL189665A (pl)
JO (1)	JO2655B1 (pl)
MA (1)	MA29787B1 (pl)
MX (1)	MX2008003170A (pl)
NO (1)	NO20081727L (pl)
NZ (2)	NZ566137A (pl)
PL (2)	PL1926483T3 (pl)
PT (2)	PT1926483E (pl)
RU (2)	RU2493840C2 (pl)
SG (1)	SG165364A1 (pl)
SI (2)	SI2295049T1 (pl)
TN (1)	TNSN08103A1 (pl)
TW (2)	TWI372620B (pl)
WO (1)	WO2007028821A2 (pl)
ZA (1)	ZA200801694B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101905023B (zh) *	2004-07-16	2012-07-11	杏林制药株式会社	有效的医药使用方法及与副作用发生的防御相关的方法
PL1806338T3 (pl)	2004-10-12	2016-07-29	Kyorin Seiyaku Kk	Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu
SI1932522T1 (sl) *	2005-10-07	2012-08-31	Kyorin Seiyaku Kk	Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RU2430925C2 (ru) *	2006-08-08	2011-10-10	Киорин Фармасьютикал Ко., Лтд.	Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
CA2659599C (en) *	2006-08-08	2014-06-17	Kyorin Pharmaceutical Co., Ltd.	Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
WO2008099781A1 (ja) *	2007-02-13	2008-08-21	Kyorin Pharmaceutical Co., Ltd.	アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
JP5452237B2 (ja)	2008-02-07	2014-03-26	杏林製薬株式会社	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
EP2305305A4 (en) *	2008-05-20	2013-02-13	Kyorin Seiyaku Kk	MEDIUM FOR INTRODUCTION / MAINTENANCE OF THE REMISSION
CA2734585A1 (en) *	2008-08-18	2010-02-25	Novartis Ag	Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
WO2011138398A1 (en) *	2010-05-06	2011-11-10	Novartis Ag	Dosage regimen of diaryl sulfide derivatives
US20130172297A1 (en) *	2010-05-06	2013-07-04	Novartis Ag	Treatment of Autoimmune Diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141421A (en) *	1991-12-17	1992-08-25	Carrier Corporation	Nested coupling mechanism for scroll machines
DE4428835A1 (de) *	1994-08-01	1996-02-08	Schering Ag	Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
EP2030614A1 (en) *	1997-02-27	2009-03-04	Novartis AG	Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
JP4152884B2 (ja) *	2001-09-27	2008-09-17	杏林製薬株式会社	ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
KR100913269B1 (ko) *	2001-09-27	2009-08-21	교린 세이야꾸 가부시키 가이샤	디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4571497B2 (ja) *	2002-09-19	2010-10-27	杏林製薬株式会社	アミノアルコール誘導体とその付加塩及び免疫抑制剤
MXPA05003254A (es) *	2002-09-24	2005-06-08	Novartis Ag	Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
EP1542662A1 (en) *	2002-09-28	2005-06-22	McNEIL-PPC, INC.	Immediate release dosage form comprising shell having openings therein
DK1602660T3 (da) *	2003-02-18	2011-05-23	Kyorin Seiyaku Kk	Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
CA2707750A1 (en) *	2003-04-08	2004-10-21	Novartis Ag	Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
WO2005014525A2 (en) *	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
EP1660449B1 (en)	2003-08-28	2009-11-18	Novartis AG	Aminopropanol derivatives
CN101905023B (zh) *	2004-07-16	2012-07-11	杏林制药株式会社	有效的医药使用方法及与副作用发生的防御相关的方法
EP2384749A1 (en) *	2004-11-29	2011-11-09	Novartis AG	Dosage regimen of an S1P receptor agonist
GB0504544D0 (en) *	2005-03-04	2005-04-13	Novartis Ag	Organic compounds

2006
- 2006-09-07 NZ NZ566137A patent/NZ566137A/en not_active IP Right Cessation
- 2006-09-07 CN CN2006800328984A patent/CN101257899B/zh not_active Expired - Fee Related
- 2006-09-07 ES ES10174280.7T patent/ES2529724T3/es active Active
- 2006-09-07 KR KR1020087008413A patent/KR101476451B1/ko not_active Expired - Fee Related
- 2006-09-07 WO PCT/EP2006/066150 patent/WO2007028821A2/en not_active Ceased
- 2006-09-07 NZ NZ588372A patent/NZ588372A/en not_active IP Right Cessation
- 2006-09-07 RU RU2011111117/15A patent/RU2493840C2/ru not_active IP Right Cessation
- 2006-09-07 RU RU2008113187/15A patent/RU2424795C2/ru not_active IP Right Cessation
- 2006-09-07 SI SI200631889T patent/SI2295049T1/sl unknown
- 2006-09-07 PL PL06793341T patent/PL1926483T3/pl unknown
- 2006-09-07 JP JP2008529636A patent/JP5244598B2/ja active Active
- 2006-09-07 PT PT06793341T patent/PT1926483E/pt unknown
- 2006-09-07 AT AT06793341T patent/ATE489948T1/de active
- 2006-09-07 ES ES06793341T patent/ES2357426T3/es active Active
- 2006-09-07 DK DK06793341.6T patent/DK1926483T3/da active
- 2006-09-07 SI SI200630937T patent/SI1926483T1/sl unknown
- 2006-09-07 SG SG201006580-3A patent/SG165364A1/en unknown
- 2006-09-07 CA CA2620554A patent/CA2620554C/en not_active Expired - Fee Related
- 2006-09-07 EP EP06793341A patent/EP1926483B1/en active Active
- 2006-09-07 US US12/065,096 patent/US20080200438A1/en not_active Abandoned
- 2006-09-07 PT PT10174280T patent/PT2295049E/pt unknown
- 2006-09-07 EP EP10174280.7A patent/EP2295049B1/en not_active Not-in-force
- 2006-09-07 JO JO2006298A patent/JO2655B1/en active
- 2006-09-07 AU AU2006289100A patent/AU2006289100B2/en not_active Ceased
- 2006-09-07 PL PL10174280T patent/PL2295049T3/pl unknown
- 2006-09-07 KR KR1020147026128A patent/KR20140117704A/ko not_active Ceased
- 2006-09-07 KR KR1020147001496A patent/KR101476591B1/ko not_active Expired - Fee Related
- 2006-09-07 DK DK10174280.7T patent/DK2295049T3/en active
- 2006-09-07 DE DE602006018629T patent/DE602006018629D1/de active Active
- 2006-09-07 MX MX2008003170A patent/MX2008003170A/es active IP Right Grant
- 2006-09-07 CA CA2820510A patent/CA2820510A1/en not_active Abandoned
- 2006-09-07 BR BRPI0615906-0A patent/BRPI0615906A2/pt not_active IP Right Cessation
- 2006-09-08 TW TW099117063A patent/TWI372620B/zh not_active IP Right Cessation
- 2006-09-08 TW TW095133326A patent/TWI376223B/zh active
2008
- 2008-02-21 IL IL189665A patent/IL189665A/en not_active IP Right Cessation
- 2008-02-21 ZA ZA200801694A patent/ZA200801694B/xx unknown
- 2008-03-06 TN TNP2008000103A patent/TNSN08103A1/en unknown
- 2008-03-17 MA MA30758A patent/MA29787B1/fr unknown
- 2008-04-07 NO NO20081727A patent/NO20081727L/no not_active Application Discontinuation
2010
- 2010-09-21 AU AU2010224355A patent/AU2010224355B2/en not_active Ceased
2011
- 2011-03-01 CY CY20111100242T patent/CY1111285T1/el unknown
2012
- 2012-10-17 JP JP2012230044A patent/JP6077265B2/ja not_active Expired - Fee Related
2014
- 2014-06-23 IL IL233328A patent/IL233328A0/en unknown
- 2014-09-29 JP JP2014199069A patent/JP2015025002A/ja not_active Withdrawn
2016
- 2016-09-30 JP JP2016193400A patent/JP2017019854A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20080046231A (ko)	2008-05-26
WO2007028821A2 (en)	2007-03-15
ATE489948T1 (de)	2010-12-15
ES2529724T3 (es)	2015-02-25
JP2013010802A (ja)	2013-01-17
JP2017019854A (ja)	2017-01-26
DK1926483T3 (da)	2011-03-14
KR20140117704A (ko)	2014-10-07
JP5244598B2 (ja)	2013-07-24
PT1926483E (pt)	2011-03-03
KR101476591B1 (ko)	2014-12-24
US20080200438A1 (en)	2008-08-21
ES2357426T3 (es)	2011-04-26
PL1926483T3 (pl)	2011-05-31
AU2010224355B2 (en)	2012-03-29
RU2493840C2 (ru)	2013-09-27
IL189665A0 (en)	2008-06-05
KR101476451B1 (ko)	2014-12-24
TWI376223B (en)	2012-11-11
CA2820510A1 (en)	2007-03-15
MX2008003170A (es)	2008-03-18
TNSN08103A1 (en)	2009-07-14
WO2007028821A3 (en)	2007-05-03
EP1926483B1 (en)	2010-12-01
JP2015025002A (ja)	2015-02-05
TW200803829A (en)	2008-01-16
HK1149906A1 (en)	2011-10-21
ZA200801694B (en)	2009-09-30
RU2424795C2 (ru)	2011-07-27
RU2011111117A (ru)	2012-09-27
JP2009507810A (ja)	2009-02-26
PT2295049E (pt)	2015-03-02
RU2008113187A (ru)	2009-10-20
DE602006018629D1 (de)	2011-01-13
AU2006289100B2 (en)	2010-07-22
SI2295049T1 (sl)	2015-03-31
CA2620554A1 (en)	2007-03-15
JP6077265B2 (ja)	2017-02-08
AU2010224355A1 (en)	2010-10-14
TW201034659A (en)	2010-10-01
IL189665A (en)	2014-07-31
CN101257899B (zh)	2012-10-03
NZ588372A (en)	2012-03-30
CY1111285T1 (el)	2015-08-05
EP1926483A2 (en)	2008-06-04
SG165364A1 (en)	2010-10-28
EP2295049B1 (en)	2014-11-26
DK2295049T3 (en)	2015-02-23
TWI372620B (en)	2012-09-21
CA2620554C (en)	2013-12-17
SI1926483T1 (sl)	2011-04-29
CN101257899A (zh)	2008-09-03
EP2295049A1 (en)	2011-03-16
NO20081727L (no)	2008-06-06
BRPI0615906A2 (pt)	2011-05-31
NZ566137A (en)	2011-05-27
MA29787B1 (fr)	2008-09-01
JO2655B1 (en)	2012-06-17
KR20140019033A (ko)	2014-02-13
AU2006289100A1 (en)	2007-03-15
IL233328A0 (en)	2014-08-31

Publication	Publication Date	Title
IL233328A0 (en)	2014-08-31	Treatment of autoimmune diseases
TW200509892A (en)	2005-03-16	Novel aminobenzophenone compounds
WO2005032471A3 (en)	2005-07-07	Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006058868A3 (de)	2006-08-03	Substituierte pteridine zur behandlung von entzündlichen erkrankungen
TW200806325A (en)	2008-02-01	Therapeutic uses of inhibitors of RTP801
WO2005051914A8 (en)	2005-08-11	Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MX2011012015A (es)	2012-04-30	Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
PL1910338T3 (pl)	2011-02-28	Związki heterotetracykliczne jako mimetyki TPO
WO2006058867A3 (de)	2006-10-26	Substituierte pteridine zur behandlung von entzündlichen erkrankungen
UA90698C2 (en)	2010-05-25	Triazole substituted aminobenzophenone compounds
MX2010000956A (es)	2010-03-01	Derivados de isoftalamida que inhiben actividad de beta-secretasa.
WO2009136997A3 (en)	2009-12-30	Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
TW200635597A (en)	2006-10-16	Substituted pteridines for the treatment of inflammatory diseases
WO2006078576A3 (en)	2006-10-05	Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
BR0306855A (pt)	2005-04-05	Método para o tratamento de distúrbios cognitivos
MX2008002166A (es)	2008-04-22	Compuestos y composiciones como mimeticos de trombopoietina (tpo).
WO2007058862A3 (en)	2007-10-11	Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
TW200633711A (en)	2006-10-01	Substituted pteridines for the treatment of inflammatory diseases
IL181713A0 (en)	2008-03-20	Use of il-17f for the treatment and/or prevention of neurological diseases
TW200505435A (en)	2005-02-16	Treatment of ocular disorders
WO2007019080A3 (en)	2008-01-17	Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
CY1116051T1 (el)	2017-02-08	Θεραπεια αυτοανοσων ασθενειων
TW200628453A (en)	2006-08-16	Triazole substituted aminobenzophenone compounds
BRPI0402756A (pt)	2006-02-21	método para o tratamento de distúrbios cognitivos
MX2007003281A (es)	2007-05-18	N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central.